AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Feb 12, 2021
31637_dirs_2021-02-11_8dcd1304-f3a4-4ea3-93ac-bde5dcff9660.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-02-07
Reporting Person: Schuth Alexander O. (COO and Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-07 | Common Stock | M | 4250 | $0.00 | Acquired | 538812 | Indirect |
| 2021-02-09 | Common Stock | S | 1262 | $74.658 | Disposed | 537550 | Indirect |
| 2021-02-09 | Common Stock | S | 206 | $75.684 | Disposed | 537344 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-07 | Restricted Stock Units | $ | M | 4250 | Disposed | Common Stock (4250) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 10686 | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
F3: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.17 to $75.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.22 to $76.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.